亚洲精品在线影院,欧美高清成人,99久久99久久久精品齐齐鬼色

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	193275-84-2
Formula :	C₂₇H₃₁Br₂ClN₄O₂
M.W :	638.82
SMILES Code :	O=C(N1CCC(CC(N2CCC([C@@H]3C4=C(Br)C=C(Cl)C=C4CCC5=CC(Br)=CN=C53)CC2)=O)CC1)N
Synonyms :	Sch66336; Sarasar
MDL No. :	MFCD06795138
InChI Key :	DHMTURDWPRKSOA-RUZDIDTESA-N
Pubchem ID :	148195

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

normal human dermal fibroblasts (NDFs)	5 μM	16 days	To investigate the effect of FTI-277 on progerin accumulation, results showed that FTI-277 significantly reduced progerin accumulation.	PMC11113360
C2C12 myotubes	2 μM	24 hours	Lonafarnib significantly improved myotube area, fusion index, and myotube diameter, indicating its protective effect against dexamethasone-induced muscle atrophy.	PMC11696026
HEp-2 cells	5 μM	48 hours	To screen the ReFRAME library and confirm the antiviral activity of Lonafarnib	PMC10853176
293 T cells	5 μM	48 hours	To evaluate the inhibitory effect of Lonafarnib on RSV F protein-induced cell fusion	PMC10853176
MCF-7	5 and 10 μM	48 hours	To observe the effects of lonafarnib on microtubule structure, results showed that lonafarnib treatment led to increased microtubule bundling	PMC1861827
A549	5-20 μM	48 hours	To assess the effects of lonafarnib on tubulin polymerization, results showed that lonafarnib treatment led to increased tubulin polymerization	PMC1861827
HEp-2 cells	57.7 ± 15.4 nM ( EC50)	72 hours	Lonafarnib inhibited RSV A2 and B01 genotypes with EC50 values of 57.7 ± 15.4 nM and 75.5 ± 4.0 nM, respectively.	PMC11163014
Human bronchial epithelial cells (HBEC)	599.9 ± 67.4 nM ( EC50)	72 hours	Lonafarnib inhibited RSV A2 and B01 replication in HBEC with EC50 values of 599.9 ± 67.4 nM and 515.0 ± 44.2 nM, respectively.	PMC11163014
SH-SY5Y	1 μM	72 hours	Lonafarnib in combination with ALK TKIs decreased cell viability and showed synergistic effects at higher concentrations	PMC11039739
KELLY	1 μM	72 hours	Lonafarnib in combination with ALK TKIs showed synergistic effects in KELLY cells, but additive effects at higher concentrations	PMC11039739

Mice	RSV infection model	Oral	60 mg/kg	twice daily for 4 days	To evaluate the effect of Lonafarnib on RSV virus load in mice, results showed that Lonafarnib significantly reduced the virus load	PMC10853176
BALB/c mice	RSV infection model	Oral	17 or 34 mg/kg	Twice daily for 4 consecutive days	Lonafarnib significantly reduced RSV replication in the BALB/c mouse model, with a 7.4-fold decrease in viral titer at 34 mg/kg dose, and alleviated lung inflammation.	PMC11163014
NSG mice	COG-N-426x PDX model	Oral	40 mg/kg	Daily for 30 days	Combination of lonafarnib with ceritinib significantly delayed tumor growth and showed strong synergistic effects during treatment, but tumors rapidly regrew after cessation of therapy	PMC11039739
Sprague-Dawley rats	Dexamethasone-induced muscle atrophy model	Intraperitoneal injection	1 μM and 5 μM	Once daily for 6 days	Lonafarnib significantly improved grip strength, muscle weight, and compound muscle action potential (CMAP) amplitudes in dexamethasone-induced muscle atrophy models, indicating its mitigation of muscle atrophy through enhanced mitochondrial function and anabolic pathways.	PMC11696026
Mice	LmnaG609G/G609G mouse model	Oral	450 mg/kg	Daily, throughout the survival period	To evaluate the effect of Lonafarnib on LmnaG609G/G609G mice, it was found to extend survival, improve body weight, and reduce kyphosis	PMC11488313
Mice	Hutchinson-Gilford progeria syndrome model	Oral	450 mg/kg	Daily, from post-weaning (P21) or P100 to P168 days	Lonafarnib improved cardiovascular function and survival, significantly reducing pulse wave velocity and improving left ventricular diastolic function.	PMC10023154

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

{[proInfo.proName]}

CAS No.: 193275-84-2

Alternative Products

Product Details of Lonafarnib

Safety of Lonafarnib

Related Pathways of Lonafarnib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT00040534	Neoplasms	Phase 1	Terminated	-	-
NCT00040547	Neoplasms	Phase 1	Completed	-	-
NCT00003956	Lymphoma Unsp... More >>ecified Adult Solid Tumor, Protocol Specific Less <<	Phase 1	Completed	-	United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Less <<
NCT00038493	Glioblastoma Multiforme	Phase 2	Completed	-	United States, Texas ... More >> UTMD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00038584	Carcinoma, Squamous Cell ... More >> Cancer of Head and Neck Less <<	Phase 1	Completed	-	United States, Texas ... More >> The University of Texas M. D. Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00034684	Leukemia Myel... More >>odysplastic Syndromes Leukemia, Myeloid, Chronic Blast Crisis Leukemia, Lymphocytic Less <<	Phase 1 Phase 2	Completed	-	-
NCT00038597	Myelogenous Leukemia, Chronic	Phase 2	Completed	-	United States, Texas ... More >> MDAnderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00073450	Carcinoma, Squamous Cell ... More >> Head and Neck Neoplasms Less <<	Phase 2	Terminated	-	-
NCT00612651	Gliosarcoma G... More >>lioblastoma Anaplastic Astrocytoma Less <<	Phase 1	Completed	-	United States, North Carolina ... More >> Duke University Health System Durham, North Carolina, United States, 27710 Less <<
NCT00020774	Liver Cancer	Phase 2	Withdrawn	-	-
NCT00006351	Bladder Cancer ... More >> Transitional Cell Cancer of the Renal Pelvis and Ureter Urethral Cancer Less <<	Phase 2	Completed	-	Netherlands ... More >> University Medical Center Nijmegen Nijmegen, Netherlands, 6500 Less <<
NCT00068757	Breast Cancer	Phase 1	Completed	-	Belgium ... More >> Institut Jules Bordet Brussels, Belgium, 1000 France Institut Curie Hopital Paris, France, 75248 Netherlands Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Amsterdam, Netherlands, 1066 CX Less <<
NCT03719313	Hepatitis Delta Virus	Phase 3	Not yet recruiting	November 1, 2021	-
NCT00005030	Colorectal Cancer ... More >> Metastatic Cancer Less <<	Phase 1	Withdrawn(No enrollment.)	-	-
NCT00083096	Brain and Central Nervous Syst... More >>em Tumors Less <<	Phase 1	Unknown	-	France ... More >> Centre de Lutte Contre le Cancer Georges-Francois Leclerc Dijon, France, 21079 Centre Regional Rene Gauducheau Nantes-Saint Herblain, France, 44805 Switzerland Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland, CH-1011 Less <<
NCT00050336	Carcinoma, Non-small-cell Lung... More >> Metastases, Neoplasm Less <<	Phase 3	Terminated	-	-
NCT00102635	Head and Neck Cancer	Phase 1	Terminated(Slow accrual.)	-	United States, Texas ... More >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03600714	Liver Disease ... More >> Hepatitis D Less <<	Phase 2	Recruiting	December 31, 2025	United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) ?? 800-411-1222 ext TTY8664111010 ?? prpl@cc.nih.gov Less <<
NCT02511431	Hepatitis D	Phase 2	Completed	-	United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00281515	Epithelial Ovarian Cancer	PHASE2	COMPLETED	2025-12-11	Charité - Universit?tsmedizin ... More >>Berlin, Campus Virchow-Klinikum, Klinik für Frauenheilkunde, Berlin, 13353, Germany\|Klinikum Bremen Mitte, Frauenklinik, Bremen, 28177, Germany\|Carl-Gustav-Carus der TU Dresden, Universit?ts-Frauenklinik, Dresden, 01307, Germany\|Ev. Krankenhaus, Frauenklinik, Düsseldorf, 40217, Germany\|Klinik für Frauenheilkunde der Univ. Erlangen, Erlangen, 91054, Germany\|Universit?tsfrauenklinik, Essen, 45147, Germany\|Klinikum der Johann Wolfgang Goethe Universit?t, Klinik für Frauenheilkunde u. Geburtshilfe, Frankfurt, 60590, Germany\|Universit?tsklinikum Freiburg, Frauenklinik, Freiburg, 79106, Germany\|Kreiskrankenhaus, Frauenklinik, Gifhorn, 38518, Germany\|Klinik u. Poliklinik für Gyn?kologie und Geburtshilfe, Greifswald, 17487, Germany\|Medizinische Hochschule, Hannover, 30625, Germany\|St. Vincentius-Krankenh?user, Karlsruhe, 76137, Germany\|Universit?tsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Gyn?kologie und Geburtshilfe, Kiel, 24105, Germany\|Klinik der Otto-von-Guericke Universit?t, Frauenklinik, Magdeburg, 39108, Germany\|Johannes-Gutenberg-Universit?t, Universit?ts-Frauenklinik, Mainz, 55101, Germany\|Klinikum der Philipps-Universit?t Marburg, Klinik für Gyn?kologie, Gyn?kologische Endokrinologie, Marburg, 35037, Germany\|Klinikum Gro?hadern, Frauenklinik, München, 81377, Germany\|Klinikum rechts der Isar der TU München, München, 81675, Germany\|Elblandkliniken, Frauenklinik, Radebeul, 01445, Germany\|Klinikum Südstadt, Rostock, 18059, Germany\|Universit?ts-Frauenklinik, Tübingen, 72076, Germany\|Universit?tsfrauenklinik, Ulm, 89075, Germany\|Dr. Horst Schmidt Klinik, Gyn?kologie u. Gyn?kologische Onkologie, Wiesbaden, 65199, Germany Less <<
NCT02511431	-		Completed	-	-
NCT00015899	Brain and Central Nervous Syst... More >>em Tumors Less <<	Phase 1	Completed	-	United States, California ... More >> UCSF Comprehensive Cancer Center San Francisco, California, United States, 94143-0372 United States, District of Columbia Children's National Medical Center Washington, District of Columbia, United States, 20010-2970 United States, Massachusetts Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, North Carolina Duke Comprehensive Cancer Center Durham, North Carolina, United States, 27710 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104-4318 Children's Hospital of Pittsburgh Pittsburgh, Pennsylvania, United States, 15213 United States, Tennessee St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105-2794 United States, Texas Texas Children's Cancer Center Houston, Texas, United States, 77030-2399 United States, Washington Children's Hospital and Regional Medical Center - Seattle Seattle, Washington, United States, 98105 Less <<
NCT00288444	Lung Cancer S... More >>oft Tissue Sarcoma Colorectal Carcinoma Breast Cancer Prostate Cancer Less <<	Phase 1	Terminated	-	United States, Georgia ... More >> Emory University Winship Cancer Institute Atlanta, Georgia, United States, 30308 Less <<
NCT00102648	Malignant Supratentorial Neopl... More >>asm Recurrent Glioblastoma Recurrent Gliosarcoma Less <<	Phase 1	Active, not recruiting	December 1, 2020	United States, Texas ... More >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01232881	-		Terminated(funding terminated)	-	United States, Indiana ... More >> Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 Less <<
NCT00916747	Progeria	Phase 2	Enrolling by invitation	July 2020	United States, Massachusetts ... More >> Children's Hospital Boston Boston, Massachusetts, United States, 02115 Less <<
NCT02430181	Chronic Hepatitis D Infection	Phase 2	Completed	-	Turkey ... More >> Ankara University Medical School Ankara, Turkey Less <<
NCT00047502	Chronic Myelogenous Leukemia	Phase 1	Completed	-	United States, Texas ... More >> M.D. Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01495585	Hepatitis D	Phase 2	Completed	-	United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT01495585	-		Completed	-	-
NCT00081510	Breast Cancer	Phase 2	Completed	-	-
NCT02968641	Chronic Delta Hepatitis	Phase 2	Unknown	-	-
NCT02430194	Chronic Hepatitis D Infection	Phase 2	Completed	-	Turkey ... More >> Ankara University Medical School Ankara, Turkey Less <<
NCT00539968	Prostate Cancer ... More >> Breast Cancer Ovarian Cancer Lung Cancer Gastric Cancer Less <<	Phase 1 Phase 2	Terminated	-	-
NCT00425607	Progeria\|Hutchinson-Gilford Sy... More >>ndrome Less <<	PHASE2	COMPLETED	2025-10-09	Children's Hospital Boston, Bo... More >>ston, Massachusetts, 02115, United States Less <<
NCT00879034	Progeria Hutc... More >>hinson-Gilford Syndrome Less <<	Phase 2	Completed	-	United States, Massachusetts ... More >> Children's Hospital Boston Boston, Massachusetts, United States, 02115 Less <<
NCT00109538	Myelodysplastic Syndromes ... More >> Leukemia, Myelomonocytic, Chronic Myelodysplasia Myelomonocytic Less <<	Phase 3	Terminated	-	-
NCT00773474	Metastatic Breast Cancer	PHASE2	TERMINATED	2025-11-10	Medical & Surgical Specialists... More >>, LLC, Galesburg, Illinois, 61401, United States\|Cancer Care Center of Southern Indiana, Bloomington, Indiana, 47403, United States\|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, 46202, United States\|Arnett Cancer Care, Lafayette, Indiana, 47904, United States\|Horizon Oncology Center, Lafayette, Indiana, 47905, United States\|Ireland Cancer Center - University Hospitals of Cleveland, Cleveland, Ohio, 44106, United States Less <<
NCT00425607	Progeria\|Hutchinson-Gilford Sy... More >>ndrome Less <<	PHASE2	COMPLETED	2025-10-09	Children's Hospital Boston, Bo... More >>ston, Massachusetts, 02115, United States Less <<
NCT00773474	Metastatic Breast Cancer	PHASE2	TERMINATED	2025-11-10	Medical & Surgical Specialists... More >>, LLC, Galesburg, Illinois, 61401, United States\|Cancer Care Center of Southern Indiana, Bloomington, Indiana, 47403, United States\|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, 46202, United States\|Arnett Cancer Care, Lafayette, Indiana, 47904, United States\|Horizon Oncology Center, Lafayette, Indiana, 47905, United States\|Ireland Cancer Center - University Hospitals of Cleveland, Cleveland, Ohio, 44106, United States Less <<
NCT00879034	-		Completed	-	-
NCT02527707	Chronic Delta Hepatitis	Phase 2	Completed	-	-
NCT02579044	Progeria	Phase 1 Phase 2	Recruiting	December 2021	United States, Massachusetts ... More >> Boston Children's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Monica E Kleinman, MD ?? ?? monica.kleinman@childrens.harvard.edu Less <<
NCT03895528	Progeria\|HGPS		APPROVED_FOR_MARKETING	-	-

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	1.57mL 0.31mL 0.16mL	7.83mL 1.57mL 0.78mL	15.65mL 3.13mL 1.57mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed